Paget disease of bone: An update

Australian Family Physician

Volumn 41, Issue 3, 2012, Pages 100-103

  Britton, Cameron ^a   Walsh, John ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Osteitis deformans; Paget disease of bone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE; RISEDRONIC ACID; ZOLEDRONIC ACID;

AGED; ARTICLE; HUMAN; MIDDLE AGED; PAGET BONE DISEASE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEITIS DEFORMANS;

EID: 84858413445     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Gardner M, Guyer P, Barker D. Radiological prevalence of Paget's disease of bone in British migrants to Australia. BMJ 1978;1:1655-7.
2. C ooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget's disease of bone. J Bone Miner Res 2006;21(Suppl 2):P3-8.
3. Walsh J. Paget's disease of bone. Med J Aust 2004;181:262-5.
4. C ooper C, Dennison E, Schafheutle K, Kellingray S, Guyer P, Barker D. Epidemiology of Paget's disease of bone. Bone 1999;24:3S-5S.
5. C ooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999;14:192-7.
6. Doyle T, Gunn J, Anderson G, Gill M, Cundy T. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002;31:616-9.
7. Siris E, Ottman R, Flaster E, Doyle T. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991;6:495-500.
8. Seton M, Choi H, Hansen M, Sebaldt R, Cooper C. Analysis of environmental factors in familial versus sporadic Paget's disease of bone - theNew England Registry for Paget's Disease of Bone. J Bone Miner Res 2003;18:1519-24.
9. Rea S, Walsh J, Ward L, Magno A, Ward B, Shaw B. Sequestome 1 muatations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-B signalling without loss of ubiquitin binding. J Bone Miner Res 2009;24:1216-23.
10. Albagha O, Visconti M, Alonso N, Langston A, Cundy T, Dargie R. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 2010;42:520-4.
11. Albagha O, Wani S, Visconti M, Alonso N, Goodman K, Brandi M. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet 2011;43:685-9.
12. Ralston S, Langston A, Reid I. Pathogenesis and management of Paget's disease of bone. Lancet 2008;372:155-63.
13. Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morisette J. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62P392L mutation to Paget's disease. Cell Metab 2011;13:23-34.
14. Solomon L. Billiard-player's fingers: an unusual case of Paget's disease of bone. BMJ 1979;1:931.
15. Lever J. Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone 2002;31:434-6.
16. H arinck H, Bijvoet O, Vellenga C, Blanksma H, Frijlink W. Relation between signs and symptoms in Paget's disease of bone. Q J Med 1986;58:133-51.
17. Reid I, Nicholson G, Weinstein R, et al. Biochemical and radiological improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996;101:341-8.
18. Fraser W, Stamp T, Creek R, Sawyer J, Picot C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J 1997;73:496-502.
19. S elby P, Davie M, Ralston S, Stone M. Guidelines of the management of Paget's disease of bone. Bone 2002;31:366-73.
20. Lyles K, Siris E, Singer F, Meunier P. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001;16:1379-87.
21. Walsh J, Attewell R, Stuckey B, et al. Treatment of Paget's disease of bone: A survey of clinical practice in Australia. Bone 2008;42:1219-25.
22. Reid I, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
23. Reid I, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res 2011;26:2261-70.
24. Reid I, Lyles K, Su G, et al. Long-term efficacy of zoledronic acid compared with risedronate in Paget's disease. Bone 2010;47(Suppl 1):OC21.
25. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.